You are here

  • Home
  • Archive
  • Volume 7, Issue 7
  • Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study …

Article Text

Article menu

Download PDFPDF

XML
Diabetes and endocrinology
Protocol
Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol
  1. Lia Bally1,2,
  2. Hood Thabit1,2,3,
  3. Martin Tauschmann1,4,
  4. Janet M Allen1,4,
  5. Sara Hartnell2,
  6. Malgorzata E Wilinska1,4,
  7. Jane Exall5,
  8. Viki Huegel6,
  9. Judy Sibayan6,
  10. Sarah Borgman6,
  11. Peiyao Cheng6,
  12. Maxine Blackburn7,
  13. Julia Lawton7,
  14. Daniela Elleri8,
  15. Lalantha Leelarathna3,
  16. Carlo L Acerini1,4,
  17. Fiona Campbell5,
  18. Viral N Shah9,
  19. Amy Criego10,
  20. Mark L Evans1,2,
  21. David B Dunger1,4,
  22. Craig Kollman6,
  23. Richard M Bergenstal10,
  24. Roman Hovorka1,4
  1. 1 Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
  2. 2 Department of Diabetes & Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  3. 3 Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
  4. 4 Department of Paediatrics, University of Cambridge, Cambridge, UK
  5. 5 Leeds Children's Hospital, Leeds, UK
  6. 6 Jaeb Center for Health Research, Tampa, Florida, USA
  7. 7 Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
  8. 8 Royal Hospital for Sick Children, Edinburgh, UK
  9. 9 Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA
  10. 10 International Diabetes Center at Park Nicollet, St Louis Park, Minnesota, USA
  1. Correspondence to Dr. Roman Hovorka; rh347{at}cam.ac.uk

Abstract

Introduction Despite therapeutic advances, many individuals with type 1 diabetes are unable to achieve tight glycaemic target without increasing the risk of hypoglycaemia. The objective of this study is to determine the effectiveness of a 3-month day-and-night home closed-loop glucose control combined with a pump suspend feature, compared with sensor-augmented insulin pump therapy in youths and adults with suboptimally controlled type 1 diabetes.

Methods and analysis The study adopts an open-label, multi-centre, multi-national (UK and USA), randomised, single-period, parallel design and aims for 84 randomised patients. Participants are youths (6–21 years) or adults (>21 years) with type 1 diabetes treated with insulin pump therapy and suboptimal glycaemic control (glycated haemoglobin (HbA1c) ≥7.5% (58 mmol/mol) and ≤10% (86 mmol/mol)). Following a 4-week run-in period, eligible participants will be randomised to a 3-month use of automated closed-loop insulin delivery combined with pump suspend feature or to sensor-augmented insulin pump therapy. Analyses will be conducted on an intention-to-treat basis. The primary outcome is the time spent in the target glucose range from 3.9 to 10.0 mmol/L based on continuous glucose monitoring levels during the 3-month free-living phase. Secondary outcomes include HbA1c at 3 months, mean glucose, time spent below and above target; time with glucose levels <3.5 and <2.8 mmol/L; area under the curve when sensor glucose is <3.5 mmol/L, time with glucose levels >16.7 mmol/L, glucose variability; total, basal and bolus insulin dose and change in body weight. Participants’ and their families’ perception in terms of lifestyle change, daily diabetes management and fear of hypoglycaemia will be evaluated.

Ethics and dissemination Ethics/institutional review board approval has been obtained. Before screening, all participants/guardians will be provided with oral and written information about the trial. The study will be disseminated by peer-reviewed publications and conference presentations.

Trial registration number NCT02523131; Pre-results.

  • type 1 diabetes
  • closed-loop
  • artificial pancreas

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/bmjopen-2017-016738

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RH, HT, MT, DBD, MLE, LL, AC, RMB and VNS codesigned the study. JL was responsible designing the interview study. RH designed and implemented the glucose controller. LB, HT and RH wrote the manuscript. All authors critically reviewed the report. No writing assistance was provided.

    • Funding JDRF, National Institute for Health Research Cambridge Biomedical Research Centre, Wellcome Strategic Award (100574/Z/12/Z).

    • Competing interests SH serves as a consultant for Novo-Nordisk and for the ONSET group and reports having received speaker/training honoraria from Medtronic. MLE reports having received speaker honoraria from Abbott Diabetes Care, Novo Nordisk and Animas and serving on advisory panels for Novo Nordisk, Abbott Diabetes Care, Medtronic, Roche and Cellnovo. RH reports having received speaker honoraria from Eli Lilly, Novo Nordisk and Astra Zeneca; serving on advisory panel for Eli Lilly and Novo Nordisk; receiving license fees from BBraun and Medtronic and having served as a consultant to BBraun. MEW has received license fees from Becton Dickinson and has served as a consultant to Beckton Dickinson. MT reports having received speaker honoraria from Novo Nordisk and Medtronic. RH and MEW report patent patents and patent applications. LL reports having received speaker honoraria from Minimed Medtronic, Animas, Sanofi and Novo Nordisk and serving on advisory panel for Animas Minimed Medtronic and Novo Nordisk. VNS had received speaking fees from the Dexcom Inc. VNS employer received research funding from T1D Exchange and Sanofi. LB, HT, JMA, JE, VH, JS, SB, PC, MB, JL, DE, CLA, FC, AC, MLE, DBD, CK and RMB declare no competing financial interests exist.

    • Patient consent Obtained.

    • Ethics approval East of England-Cambridge East Research Ethics Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.